Advertisement
News
Advertisement

Heart valves: Three-year Sapien data buoy Edwards Lifesciences

Thu, 10/25/2012 - 12:22pm
Mass Device

Edwards Lifesciences' Sapien transcatheter aortic valve implantation system shows sustained and growing survival benefits out to 3 years among inoperable patients with severe aortic stenosis.

Edwards Lifesciences Sapien TAVI

Edwards Lifesciences' (NYSE:EW) Sapien transcatheter aortic valve implantation system, the only TAVI device on the U.S. market, demonstrated sustained and increasing survival benefits out to 3 years among inoperable heart failure patients, according to newly unveiled study results.

Data from Cohort B of Edwards' Partner trials showed that the 1-year survival benefit seen in prior studies was sustained out to 3 years and increased over time, with a widening gap in mortality benefit for TAVI patients compared with a "standard therapy" group.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading